secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caris Life Sciences, Inc. (CAI)
CIK:        0002019410
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0002019410-26-000040
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caris Life Sciences Q1 revenue up 79% to $216.2M, net loss narrows to $0.5M
---------------------------------------------------------------------------

- Revenue $216.2M (+79% YoY); gross margin 65% vs 47% a year ago.
- Net loss $0.5M vs $102.6M loss in Q1 2025; positive Adj. EBITDA $26.2M.
- Completed ~52,800 clinical cases (+15% YoY); reaffirms FY2026 revenue guidance $1.0-$1.02B.
- Free cash flow positive $22.5M, inclusive of $30.5M annual bonus payments.
- Launched MolDX-approved Caris ChromoSeq; refinanced $400M credit facility with Blue Owl/Blackstone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/cai-20260507.htm
  HTML page:      https://secwatch.observer/filing/0002019410-26-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer